Independent register of U.S. FDA drug recalls · updated Oct 10, 2026
RxRecalls Get alerts
Class II · Moderate risk Ongoing Initiated Mar 6, 2026 (7 months ago)

Semaglutide-Glycine-Cyanocobalamin Injectable

Class II — Moderate risk. May cause temporary or reversible harm; serious harm unlikely.

Why it was recalled

Lack of Assurance of Sterility

Cause type: Sterility / contamination

A product that must be sterile could not be assured sterile, or was contaminated. A top reason for injectables, eye drops and IV products - loss of sterility assurance can lead to serious infections. All sterility / contamination recalls.

What was recalled

Semaglutide-Glycine-Cyanocobalamin Injectable, 2.5 mg, 5 mg, 1 MG/ML, 0.5 mL vials, Rx only, Northwest Compounders, Beaverton, OR

Drug: Cyanocobalamin

Recalling firm
Payless Compounders, LLC
Origin
OR, United States
Initiated by
Voluntary: Firm initiated
FDA recall number
D-0471-2026 · FDA notice

Check, then ask. Class II means harm is possible but usually temporary or reversible. Find the lot number on your package; if it matches, ask your pharmacist about a replacement. Do not simply stop a prescribed medication on your own - the gap can be riskier than the recall.

Other Cyanocobalamin recalls

See all
Class II · Moderate risk

Cyanocobalamin injection USP

Presence of Particulate Matter: Product contaminated with particulate matter identified as hair, glass and/or paraformaldehyde

Ongoing Particulate / foreign matter American Regent, Inc. NDC 0517-0032-01 D-0793-2026
Class II · Moderate risk

Cyanocobalamin injection USP

Presence of Particulate Matter: Product contaminated with particulate matter identified as hair, glass and/or paraformaldehyde

Ongoing Particulate / foreign matter American Regent, Inc. NDC 0517-0031-01 D-0792-2026

Other sterility / contamination recalls from 2026

All sterility / contamination recalls